Teva touts positive Phase III for nasal aerosol allergy drug; BDSI wins soluble film cancer drug patent fight

> Teva Pharmaceutical ($TEVA) is touting positive results from four Phase III studies of its QNASLTM dry nasal aerosol corticosteroid to treat seasonal allergies. Release

> CRO Particle Sciences has acquired exclusive rights to Lyotropic Therapeutics' LyoCell patent portfolio. The technology is designed to improve solubility and stability for a wide range of potential drugs, and also increase how effectively they're delivered. Release

> Pono acquired three drug technologies developed by the University of Hawaii, including a nanocarrier drug delivery system, Pacific Business News reports. Story

> The use of microneedle skin patches is more effective at delivering a flu vaccine in mice than injections under the skin or through muscles, according to a new study. Release

> The U.S. Patent Office has again rejected all claims filed by MonoSol against BioDelivery Sciences International ($BDSI) regarding Onsolis, a soluble film cancer pain drug, after reexamining three patents. Release

And Finally… Scientists are developing a number of innovative drug delivery vehicles for sustained-release glaucoma treatments, but obstacles remain before such tech will be widely used, a speaker at the American Glaucoma Society annual meeting said. Story

Suggested Articles

Takeda forged a feasibility pact to see whether it could pair a plasma-based therapy with Elektrofi's microparticle delivery tech.

RNA nanoparticles can squeeze into tumors and exit swiftly through the kidney, perfect for targeted delivery of cancer drugs, an OSU team says.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.